BioAge Labs develops drug candidates for cardiometabolic diseases, using human aging biology to identify its drug targets. BIOA reports earnings on Thu, Nov 5, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 12 | UBS | Initiated | Hold | |
| Sep 9 | Roth Capital | Target lowered | Buy | |
| Aug 3 | BTIG | Reiterated | Buy | |
| Jul 31 | Needham | Maintained | Buy | |
| May 27 | Roth Capital | Initiated | Buy |
Whale Options Flow
90DNo whale options trades in BIOA in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BIOA is in one of them and how their past BIOA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered BIOA in an article yet. Here's the latest on the wider market.
About BioAge Labs
BioAge Labs is a biopharmaceutical company based in Emeryville, California, that develops drug candidates for chronic cardiometabolic diseases such as heart disease, diabetes and obesity. Its approach uses human datasets from long-term biobanked samples and health records to find biological pathways linked to aging. Its lead candidate, BGE-102, is an oral NLRP3 inhibitor being studied for cardiovascular risk and diabetic macular edema. The company is also developing apelin receptor agonists for obesity and works with Eli Lilly and Novartis on earlier stage programs.
- Headquarters
- Emeryville, CA